QUICK LINKS
MAIN MENU
CONNECT WITH US

Button

Clinical Trial Details

Title
CY 5022: A Phase 2, Multi-center, Double-blind, Randomized, Dose-ranging, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of CK-2127107 in Patients with Amyotrophic Lateral Sclerosis (ALS)
Study Description

CK 2127107 is being investigated as a potential new therapy for the improvement of skeletal muscle function in conditions associated with muscle weakness or fatigue such as Amyotrophic Lateral Sclerosis (“ALS”). The main purpose of this research study is to evaluate and measure the pharmacodynamics (PD) of CK 2127107. Pharmacodynamics measures how the drug may work in the body and the relationship between the amount of drug taken and its effect on the body.

You will take the study drug (CK 2127107 or placebo) twice a day for twelve weeks, but only once at the end of the study (Week 12 visit). If your study doctor determines that you are unable to tolerate taking the study drug at any time, you will be withdrawn (unable to participate in) from the remainder of the research study.

Investigators

Principal Investigator
Michael T. Pulley, M.D., Ph.D.
Neurology

Resources

News & Announcements

Upcoming Events

There are currently no events to display. Check back soon!